Comparing the current results to its competitors, Jasper Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.1 %, recorded in the same quarter.
Jasper Therapeutics Inc 's Comment on Competition and Industry Peers
The company’s briquilimab KIT targeted therapeutic program faces competition from several firms developing treatments for mast cell diseases. Competitors include Celldex Therapeutics, Inc., which is developing an antibody to KIT; Blueprint Medicines, which is developing a small molecule KIT inhibitor; Novartis, Inc., which is developing a small molecule inhibitor of Bruton's Tyrosine Kinase; Sanofi Aventis, Inc., which is developing an antibody to the Interleukin 4 receptor alpha; and Evommune, Inc., which is developing a small-molecule antagonist of MRGPRX2. These competitors are developing products targeting the same domain of conditions as the company’s product candidate.
September 24, 2025
In a significant development for investors in the biotech sector, Pomerantz LLP, a well-regarded law firm known for its dedication to defending shareholder rights, has announced the filing of a class action lawsuit against Jasper Therapeutics, Inc. (NASDAQ: JSPR) and certain officers of the company. The case, formally registered in the United States District Court for the Northern District of California under docket number 25-cv-08010, targets alleged violations of federal securities laws that purportedly occurred during a critical period for the company.The lawsuit encompasses a class of individuals and entities that acquired Jasper securities between November 30, 2023, and July 3, 2025 a timeframe now refe...
September 21, 2025
Investor Alert: A Close Examination of Jasper Therapeutics Amid Securities Class Action Announcement and Competitive Revenue Decline In a significant development for investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR), the Rosen Law Firm, known for its advocacy of investor rights, has announced the filing of a class action lawsuit. This legal pursuit is specifically geared toward protecting individuals who purchased securities of Jasper Therapeutics during a defined class period from November 30, 2023, to July 3, 2025. Investors have been urged to secure legal counsel before the critical deadline of November 18, 2025, to potentially serve as lead plaintiffs. This move highlights the increasing scrutiny on ...
October 14, 2024
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria: A New Hope for Patients Jasper Therapeutics, a pioneering biopharmaceutical company focused on providing transformative therapies for patients, proudly announced encouraging results from its SPOTLIGHT study involving Briquilimab for the treatment of Chronic Inducible Urticaria (CIndU). The preliminary findings show that an impressive 14 out of 15 participants in the trial achieved a clinical response, marking a significant advancement in the therapeutic landscape for this challenging condition. Understanding Chronic Inducible Urticaria Chronic Inducible Urticaria is a debilitating condition character...
September 10, 2024
In recent years, the landscape of biotechnology has been enriched by innovative therapeutic approaches aimed at addressing unmet medical needs, particularly in the realm of allergic diseases. Jasper Therapeutics, Inc. (Nasdaq: JSPR), a burgeoning clinical-stage biotechnology company, is at the forefront of this endeavor with its novel antibody therapy, briquilimab. This article explores the promising developments surrounding briquilimab, highlighting recent announcements regarding clinical trial clearances and the company s ongoing commitment to addressing mast cell-driven diseases, including asthma and chronic urticaria. Briquilimab: A Novel Approach to Treating Mast Cell-Driven Diseases Briquilimab is a mo...
March 19, 2024
Jasper Therapeutics, a biotechnology company specializing in the development of briquilimab, a unique antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases, has made significant progress in its research. Recent announcements regarding the dosing of the first patient in the Phase 1b/2a SPOTLIGHT Clinical Study and the presentation of preclinical briquilimab data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting highlight the company s dedication to advancing the treatment of chronic inducible urticaria (CIndU) and related conditions.Facts:1. Phase 1b/2a SPOTLIGHT Clinical Study: Jasper Therapeutics has commenced the Phase 1b/2a clinical trial of briquilimab in s...
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Sources:
Jasper Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Jasper Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
